Liquidseq Lung Cancer Panel (72 Genes)

What is Liquidseq Lung cancer panel test?

The Liquidseq Lung cancer panel is a blood-based NGS test that analyzes ctDNA to profile genomic alterations in NSCLC and other lung cancers. It covers actionable and resistance genes such as EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, and ERBB2/HER2. It supports baseline diagnostic genotyping and ongoing monitoring of molecular evolution and resistance with a minimally invasive approach and faster turnaround than repeat tissue procedures.

Why consider Liquidseq Lung cancer panel test?

• To identify specific genetic mutations in lung cancer without needing a tissue biopsy.

• To guide targeted therapy decisions based on the tumor’s genetic profile.

• To monitor treatment response and detect potential resistance mutations.

• To provide a less invasive alternative to traditional biopsy methods.

• To support early detection of genetic changes that may affect prognosis and treatment options.

Who should get tested for Liquidseq Lung cancer panel test in Kozhikode?

• Patients diagnosed with lung cancer who need detailed genetic information for treatment planning.

• Individuals who cannot undergo tissue biopsy due to medical reasons.

• Patients requiring monitoring for tumor mutation changes during or after treatment.

• Healthcare providers may recommend this test to tailor therapies and improve clinical outcomes.

More Information about Liquidseq Lung cancer panel test in Kozhikode

OTHER NAMES: Liquid biopsy lung cancer panel, Circulating tumor DNA (ctDNA) lung panel, Lung cancer genetic mutation test, ctDNA lung cancer NGS panel, liquidseq lung cancer panel 72 genes, lung cancer liquid biopsy 72, ctdna lung panel, nsclc liquid biopsy panel, lung cancer blood gene test 72

NSCLC stands for non-small cell lung cancer, the most common category of lung cancer that includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and is managed with combinations of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy based on stage and biomarkers. NSCLC (non-small cell lung cancer) is the most common type of lung cancer, making up about 80% of all lung cancer cases. It is a broad term for several types of epithelial lung cancers, with the main subtypes being adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.